(Non-invasive prenatal testing)
NIPT is a highly accurate prenatal screening test that analyses foetal DNA in the mother's blood for potential chromosomal abnormalities such as Down syndrome.
This test can be performed as early as 10th week of gestation through a simple and safe blood draw.
Painless and highly accurate
Through our Partners carefully selected by our in-house experts,
THAI StemLife offers non-invasive prenatal testing ("NIPT") services to expectant mothers through
obstetricians allover Thailand.
Already many years ago in 1997 we knew that maternal plasma contains DNA from an ongoing pregnancy the form of cell-free fetal DNA(cffDNA). Rapid advances in molecular biology analysis techniques have led to the development of next‐generation sequencing (NGS), have given us the possibility to capture and analyze cffDNA. With a simple and safe blood draw, chromosomal disorders like trisomy 21(Down syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome), sex chromosome aneuploidies (SCA) as well as so called microdeletions can be detected with high accuracy (>99%) as early the 9th week of gestation. Apart from being an easy and noninvasive method, current data also reveal that NIPT is more accurate than conventional first-trimester screening (1).
The updated American College of Obstetrics and Gynecology (ACOG) and Society of Maternal Fetal Medicine (SMFM) guideline in August 2020 (2, 3), recommends offering screening options for all pregnancies regardless of maternal age or prior risk. It also concludes that, based on Level A evidence, NIPT is the most sensitive and specific screening test available for common fetal aneuploidies (chromosomal abnormalities).
Considering that amniocentesis may result in miscarriage (3), NIPT is a valuable and important option for pregnant women who are at increased risk and an important tool to improve the overall health and well‐being of all pregnant women.
The updated American College of Obstetrics and Gynecology (ACOG) and Society of Maternal Fetal Medicine (SMFM) guideline in August 2020 (2, 3), recommends offering screening options for all pregnancies regardless of maternal age or prior risk.
1. J Obstet Gynaecol Res. 2020 Aug;46(8):1246-1254. doi: 10.1111/jog.14268. Epub 2020 Jun 17.
2. American College of Obstetrics and Gynecology (ACOG) guidelines (Aug 17, 2020) at ACOG.org
3. Society of Maternal Fetal Medicine guidelines (Aug 17, 2020) at SMFM.org